Resumen de Fungal coinfection/superinfection in COVID-19 patients in a tertiary hospital in Mexico

Eduardo García Salazar, Sandra Benavidez López, Alexandro Bonifaz, Emma Alejandra Hernández Mendoza, Xóchitl Ramírez Magaña, María Reyes Montes, Esperanza Duarte Escalante, Gustavo Acosta Altamirano, María Guadalupe Frías De León

• español

  Introduction. Data on the prevalence of fungal coinfections/superinfections in patients with COVID-19 are limited.Objective. To describe the prevalence of fungal coinfections/superinfections in patients with COVID-19, as well as risk factors and demographic, clinical, and microbiological characteristics in a tertiary hospital in Mexico. Material and methods. Patients with a confirmed COVID-19 diagnosis and a confirmed fungal infection hospitalized in the ICU from March 2020–December 2021 were included. Data on age, sex, comorbidities, hospital length of stay (days), laboratory (ferritin) and microbiological results, treatment for COVID-19, antifungal therapy, and outcome were obtained from the clinical record. Results. 11/740 patients met the inclusion criteria. The coinfection and superinfection rates were 0.3% and 1.2%, respectively. The most affected population was male adults. The coinfections/superinfections diagnosed were candiduria and candidemia, caused by Candida albicans, C. tropicalis, C. glabrata, C. lusitaniae, and Kluyveromyces marxianus (C. kefyr). In addition, tracheobronchitis due to Aspergillus fumigatus was found. The most used antifungals were fluconazole and caspofungin. The lethality in patients with fungal coinfections and superinfections was 50% and 22%, respectively. The length of hospital stay was 11-65 days. Eight patients required mechanical ventilation and six received corticosteroids. The main comorbidity was diabetes mellitus (81.8%). Conclusions. The rate of fungal coinfections/superinfections in COVID-19 patients was low, but the lethality found urges for routine fungal screening in patients with severe COVID-19 to timely detect fungal infections that may further compromise the patient's life.

• English

  Introduction: Data on the prevalence of fungal coinfections/superinfections in patients with COVID-19 are limited. Objective: Describe the prevalence of fungal coinfections/superinfections in patients with COVID-19, as well as risk factors and demographic, clinical, and microbiological characteristics in a tertiary hospital in Mexico. Material and methods: Patients with a confirmed COVID-19 diagnosis and a confirmed fungal infection hospitalized in the ICU from March 2020–December 2021 were included. Data on age, sex, comorbidities, hospital length of stay (days), laboratory (ferritin) and microbiological results, treatment for COVID-19, antifungal therapy, and outcome were obtained from the clinical record. Results: 11/740 patients met the inclusion criteria. The coinfection and superinfection rates were 0.3% and 1.2%, respectively. The most affected population was male adults. The coinfections/superinfections diagnosed were candiduria and candidemia, caused by Candida albicans, C. tropicalis, C. glabrata, C. lusitaniae, and Kluyveromyces marxianus (C. kefyr). In addition, tracheobronchitis due to Aspergillus fumigatus was found. The most used antifungals were fluconazole and caspofungin. The lethality in patients with fungal coinfections and superinfections was 50% and 22%, respectively. The length of hospital stay was 11-65 days. Eight patients required mechanical ventilation and six received corticosteroids. The main comorbidity was diabetes mellitus (81.8%). Conclusions: The rate of fungal coinfections/superinfections in COVID-19 patients was low, but the lethality found urges for routine fungal screening in patients with severe COVID-19 to timely detect fungal infections that may further compromise the patient's life.